title: [A study on seroprevalence of anti-HAV IgG in adults of 4 cities in China].
abstract: OBJECTIVE
  To investigate the seroprevalence of anti-HAV IgG in adults of 4 cities in China.
  
  
  METHODS
  Serum samples were collected from 2390 local residents aged between 20 to 88 years from Beijing, Shanghai, Wuhan and Guangzhou. The anti-HAV IgG in sera was detected with a microparticle enzyme immunoassay (MEIA).
  
  
  RESULTS
  The anti-HAV IgG seroprevalence in female of 30 to 39 years in Beijing (64.58%, 62/96) was higher than that in male (45.57% 36/79)) (x(2) = 6.358, P = 0.012). It increased with age in adults of Beijing and Guangzhou. The rates were 54.22 % (90/166), 56.00% (98/175) and 67.18% (88/131) for the 20-, 30- and 40-49 age groups in Beijing (x(2) = 4.76, P = 0.03); and 52.83% (56/106), 52.50% (63/120), 82.46% (94/114), 89.80% (88/98) and 96.77% (60/62) for the 20-, 30-, 40-, 50- and 60-88 age groups in Guangzhou, respectively (x(2) = 72.58, P less than 0.01). This trend was not found in Shanghai and Wuhan (x2 = 0.96, 2.99; P = 0.33, 0.08 respectively). The seroprevalence rates of anti-HAV IgG in the 20 to 39 age group of Beijing, Shanghai, Guangzhou and Wuhan were 55.13% (188/341), 63.93% (429/671), 52.65% (119/226) and 78.37% (308/393), respectively.
  
  
  CONCLUSIONS
  The seroprevalence rates of anti-HAV IgG in young adults aged 20 to 39 years of the four cities are relatively low, and HAV vaccination should be suggested for the susceptible population of this age group in China.
authors.affiliation: Peking University Health Science Center, Department of Microbiology, Beijing 100191, China.
authors.forename: Yuan-yuan
authors.initials: YY
authors.lastname: Cheng
authors.forename: Jing-jing
authors.initials: JJ
authors.lastname: Nie
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.forename: Jin-lin
authors.initials: JL
authors.lastname: Hou
authors.forename: Xin-xin
authors.initials: XX
authors.lastname: Zhang
authors.forename: Qing
authors.initials: Q
authors.lastname: Ning
authors.forename: Xiu-yuan
authors.initials: XY
authors.lastname: Gao
authors.forename: Hong-fang
authors.initials: HF
authors.lastname: Ding
authors.forename: Xue-en
authors.initials: XE
authors.lastname: Liu
authors.forename: Hui
authors.initials: H
authors.lastname: Zhuang
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D002681:China / Q000453:epidemiology; D005260:Female; D006506:Hepatitis A / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D035922:Hepatitis A Antibodies / Q000097:blood*; D017957:Hepatitis A Virus, Human / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008875:Middle Aged; D016036:Seroepidemiologic Studies; D017678:Sex Distribution; D014505:Urban Population; D055815:Young Adult
chemical_list: D035922:Hepatitis A Antibodies; D007074:Immunoglobulin G